Medicines planning
48 results
Applied filters
Exagamglogene autotemcel (Casgevy®)
13 February 2026This document highlights key areas where Chief Pharmacists should focus pharmaceutical expertise prior to implementation of exagamglogene autotemcel.
Marketed CAR-T therapy
13 February 2026This document outlines key areas where Chief Pharmacists should focus pharmaceutical expertise prior to an organisation implementing CAR-T therapy.
Costing clinical trials of ATIMPs using the NIHR iCT
11 February 2026Guidance to support and promote consistent pharmacy costing for commercial clinical trials involving ATIMPs.
New Medicines News
4 February 2026New Medicines News is produced by the SPS Horizon Scanning Service. It highlights recent new product launches and significant medicines regulatory changes.
The licence and supporting evidence for aflibercept biosimilars
4 February 2026Aflibercept 2mg biosimilars are available for NHS use. Learn about supporting evidence and differences.
Preparing to use aflibercept 2mg biosimilar
3 February 2026Aflibercept 2mg biosimilars for use in ophthalmology are available for NHS use. We offer general information and implementation advice.
The licence and supporting evidence for omalizumab biosimilar
21 January 2026One omalizumab biosimilar is currently available: Omlyco. Learn about the licensed indications, available preparations, supporting evidence and key differences.
Preparing to use omalizumab biosimilar
20 January 2026One omalizumab biosimilar (Omlyclo) is available and other biosimilars are in development. We offer general information and implementation advice.
Preparing to use denosumab 60mg biosimilar
16 January 2026Biosimilars of denosumab 60mg (Prolia) are available. We offer general information and implementation advice.
The licence and supporting evidence for denosumab 120mg biosimilars
16 January 2026Denosumab 120mg biosimilars are licensed. Learn about indications, formulations, supporting evidence and differences.